{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:46:34Z","timestamp":1793213194025,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341076"],"award-info":[{"award-number":["82341076"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Rare diseases, though individually uncommon, collectively affect a significant portion of the population. However, their epidemiology in China remains underexplored. A population-based rare disease registry comprising 14.31\u00a0million individuals was conducted between 2012 and 2023 by the Beijing Municipal Health Big Data and Policy Research Center. Rare disease cases were identified via ICD-10 codes mapped to China\u2019s national rare disease lists (2018 and 2023) and international databases. Age-standardized incidence rates (ASIR) were calculated per 100,000 person-years with 95% confidence intervals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our analysis identified 12,371 rare disease cases, with the overall ASIR increasing from 6.109 in 2012 to 7.394 in 2023. Rare neurologic diseases accounted for 52.12% of cases, followed by systemic and rheumatologic diseases (16.89%) and rare neoplastic diseases (9.99%). The most frequently diagnosed rare diseases included generalized myasthenia gravis, ANCA-associated vasculitis, and malignant melanoma. Significant sex-based differences were observed, with female patients more affected by systemic and rheumatologic conditions, while male patients showed a higher incidence of respiratory disorders. Pediatric patients predominantly presented with inborn errors of metabolism and rare immune diseases. Comparisons with global data revealed notable disparities, such as a higher prevalence of Wilson\u2019s disease and a lower incidence of amyotrophic lateral sclerosis (ALS) in China.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study represents the first large-scale, population-based analysis of rare diseases in China, revealing distinct epidemiological patterns. These findings underscore the critical need for healthcare policies that address the unique challenges posed by rare diseases in China.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03933-8","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:18:00Z","timestamp":1754579880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Spectrum and epidemiology of rare diseases in a Chinese natural population of 14.31\u00a0million residents, 2012\u20132023"],"prefix":"10.1186","volume":"20","author":[{"given":"Ming-Jia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao-Miao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-Qi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo-Ning","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Peng","family":"heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5430-2149","authenticated-orcid":false,"given":"Jin-Kui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"2","key":"3933_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.medj.2024.01.003","volume":"5","author":"H Cederroth","year":"2024","unstructured":"Cederroth H, Gahl WA, Landoure G, Zhang S, Bolz-Johnson M. Rare disease day: amplifying voices, advocating hope. Med. 2024;5(2):103\u20135.","journal-title":"Med"},{"issue":"2","key":"3933_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y, Rath A. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165\u201373.","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"3933_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5582\/irdr.2018.01056","volume":"7","author":"J He","year":"2018","unstructured":"He J, Kang Q, Hu J, Song P, Jin C. China has officially released its first National list of rare diseases. Intractable Rare Dis Res. 2018;7(2):145\u20137.","journal-title":"Intractable Rare Dis Res"},{"issue":"4","key":"3933_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5582\/irdr.2024.01061","volume":"13","author":"J Li","year":"2024","unstructured":"Li J, Liu M, Li H, Zhang X, Xiang X, Wang Y, Wang S, Han J, Lu Y. Classification and epidemiologic analysis of 86 diseases in china\u2019s second list of rare diseases. Intractable Rare Dis Res. 2024;13(4):213\u201326.","journal-title":"Intractable Rare Dis Res"},{"issue":"1","key":"3933_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5582\/irdr.2022.01034","volume":"11","author":"Y Lu","year":"2022","unstructured":"Lu Y, Han J. The definition of rare disease in China and its prospects. Intractable Rare Dis Res. 2022;11(1):29\u201330.","journal-title":"Intractable Rare Dis Res"},{"issue":"4","key":"3933_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, Iannaccone ST, Kuntz NL, Pena LDM, Shieh PB, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284\u201393.","journal-title":"Lancet Neurol"},{"issue":"18","key":"3933_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, et al. Single-Dose Gene-Replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"10097","key":"3933_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, McCague S, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849\u201360.","journal-title":"Lancet"},{"issue":"1","key":"3933_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40259-015-0116-7","volume":"29","author":"BA Baldo","year":"2015","unstructured":"Baldo BA. Enzymes approved for human therapy: indications, mechanisms and adverse effects. BioDrugs. 2015;29(1):31\u201355.","journal-title":"BioDrugs"},{"issue":"21","key":"3933_CR10","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1056\/NEJMe1010123","volume":"363","author":"MJ Welsh","year":"2010","unstructured":"Welsh MJ. Targeting the basic defect in cystic fibrosis. N Engl J Med. 2010;363(21):2056\u20137.","journal-title":"N Engl J Med"},{"issue":"3","key":"3933_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/d41573-023-00177-8","volume":"23","author":"R Chen","year":"2024","unstructured":"Chen R, Liu S, Han J, Zhou S, Liu Y, Chen X, Zhang S. Trends in rare disease drug development. Nat Rev Drug Discovery. 2024;23(3):168\u20139.","journal-title":"Nat Rev Drug Discovery"},{"key":"3933_CR12","doi-asserted-by":"crossref","unstructured":"Tambuyzer E, Vandendriessche B, Austin CP, Brooks PJ, Larsson K, Miller Needleman KI, Valentine J, Davies K, Groft SC, Preti R et al. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat Rev Drug Discovery 2020;19(2).","DOI":"10.1038\/s41573-019-0049-9"},{"key":"3933_CR13","unstructured":"Orphadata. (2025). Orphadata: Open access portal for rare diseases knowledge. https:\/\/www.orphadata.com\/. (Accessed: 2025-03-24)."},{"issue":"Suppl 4","key":"3933_CR14","doi-asserted-by":"publisher","first-page":"iv9","DOI":"10.1093\/ndt\/gfu094","volume":"29","author":"S Parker","year":"2014","unstructured":"Parker S. The pooling of manpower and resources through the establishment of European reference networks and rare disease patient registries is a necessary area of collaboration for rare renal disorders. Nephrol Dialysis Transplantation: Official Publication Eur Dialysis Transpl Association - Eur Ren Association. 2014;29(Suppl 4):iv9\u2013i14.","journal-title":"Nephrol Dialysis Transplantation: Official Publication Eur Dialysis Transpl Association - Eur Ren Association"},{"key":"3933_CR15","unstructured":"Orphadata. (2025). Alignments. https:\/\/www.orphadata.com\/alignments\/. (Accessed: 2025-03-24)."},{"key":"3933_CR16","unstructured":"Orphadata. (2025). Epidemiology. https:\/\/www.orphadata.com\/epidemiology\/. (Accessed: 2025-03-24)."},{"key":"3933_CR17","unstructured":"Orphadata. (2025). Linearisation. https:\/\/www.orphadata.com\/linearisation\/. (Accessed: 2025-03-24). In."},{"key":"3933_CR18","doi-asserted-by":"crossref","unstructured":"Chiu ATG, Chung CCY, Wong WHS, Lee SL, Chung BHY. Healthcare burden of rare diseases in Hong Kong\u2013 adopting orphacodes in ICD-10 based healthcare administrative datasets. Orphanet J Rare Dis 2018;13(1).","DOI":"10.1186\/s13023-018-0892-5"},{"key":"3933_CR19","doi-asserted-by":"crossref","unstructured":"Mazzucato M, Vison\u00e0 Dalla Pozza L, Minichiello C, Toto E, Vianello A, Facchin P. Estimating mortality in rare diseases using a population-based registry, 2002 through 2019. Orphanet J Rare Dis 2023;18(1).","DOI":"10.1186\/s13023-023-02944-7"},{"issue":"10188","key":"3933_CR20","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","volume":"393","author":"L Durcan","year":"2019","unstructured":"Durcan L, O\u2019Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332\u201343.","journal-title":"Lancet"},{"issue":"5","key":"3933_CR21","doi-asserted-by":"publisher","first-page":"A311","DOI":"10.1016\/j.autrev.2009.11.003","volume":"9","author":"B Ranque","year":"2010","unstructured":"Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev. 2010;9(5):A311\u2013318.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"3933_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrrheum.2010.231","volume":"7","author":"WJ Kovacs","year":"2011","unstructured":"Kovacs WJ, Olsen NJ. Sexual dimorphism of RA manifestations: genes, hormones and behavior. Nat Rev Rheumatol. 2011;7(5):307\u201310.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"3933_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41392-024-01929-7","volume":"9","author":"Y Shi","year":"2024","unstructured":"Shi Y, Ma J, Li S, Liu C, Liu Y, Chen J, Liu N, Liu S, Huang H. Sex difference in human diseases: mechanistic insights and clinical implications. Signal Transduct Target Ther. 2024;9(1):238.","journal-title":"Signal Transduct Target Ther"},{"issue":"9559","key":"3933_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(07)60196-2","volume":"369","author":"A Ala","year":"2007","unstructured":"Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson\u2019s disease. Lancet. 2007;369(9559):397\u2013408.","journal-title":"Lancet"},{"issue":"Suppl 3","key":"3933_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/hae.14042","volume":"27","author":"A Srivastava","year":"2021","unstructured":"Srivastava A. Diagnosis of haemophilia and other inherited bleeding disorders - Is a new paradigm needed? Haemophilia. 2021;27(Suppl 3):14\u201320.","journal-title":"Haemophilia"},{"issue":"9771","key":"3933_CR26","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(10)60680-0","volume":"377","author":"CB Forrest","year":"2011","unstructured":"Forrest CB, Bartek RJ, Rubinstein Y, Groft SC. The case for a global rare-diseases registry. Lancet. 2011;377(9771):1057\u20139.","journal-title":"Lancet"},{"issue":"1","key":"3933_CR27","first-page":"3","volume":"1","author":"P Song","year":"2012","unstructured":"Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in asia: current status and future perspectives. Intractable Rare Dis Res. 2012;1(1):3\u20139.","journal-title":"Intractable Rare Dis Res"},{"issue":"4","key":"3933_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10545-007-0666-z","volume":"30","author":"OA Bodamer","year":"2007","unstructured":"Bodamer OA, Hoffmann GF, Lindner M. Expanded newborn screening in Europe 2007. J Inherit Metab Dis. 2007;30(4):439\u201344.","journal-title":"J Inherit Metab Dis"},{"issue":"10204","key":"3933_CR29","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(19)32179-8","volume":"394","author":"S Zhang","year":"2019","unstructured":"Zhang S, Chen L, Zhang Z, Zhao Y. Orphan drug development in china: progress and challenges. Lancet. 2019;394(10204):1127\u20138.","journal-title":"Lancet"},{"key":"3933_CR30","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.2147\/DDDT.S506112","volume":"19","author":"X Wen","year":"2025","unstructured":"Wen X, Jin G, Wu C. Visual research of global orphan drug from a bibliometric perspective. Drug Des Devel Ther. 2025;19:4201\u201320.","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"3933_CR31","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1002\/mds.28207","volume":"35","author":"JOT Sipila","year":"2020","unstructured":"Sipila JOT, Hietala M, Kyto V, Kaasinen V. Wilson\u2019s disease in finland: A nationwide Population-Based study. Mov Disord. 2020;35(12):2323\u20137.","journal-title":"Mov Disord"},{"key":"3933_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia Gravis. BMC Neurol. 2010;10:46.","journal-title":"BMC Neurol"},{"issue":"4","key":"3933_CR33","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/jnnp.65.4.492","volume":"65","author":"NP Robertson","year":"1998","unstructured":"Robertson NP, Deans J, Compston DA. Myasthenia gravis: a population based epidemiological study in cambridgeshire, England. J Neurol Neurosurg Psychiatry. 1998;65(4):492\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"3933_CR34","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1212\/01.WNL.0000050461.05432.C5","volume":"60","author":"JM Aragones","year":"2003","unstructured":"Aragones JM, Bolibar I, Bonfill X, Bufill E, Mummany A, Alonso F, Illa I. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology. 2003;60(6):1024\u20136.","journal-title":"Neurology"},{"issue":"5","key":"3933_CR35","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1212\/WNL.47.5.1233","volume":"47","author":"LH Phillips","year":"1996","unstructured":"Phillips LH 2nd, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia Gravis. Neurology. 1996;47(5):1233\u20138.","journal-title":"Neurology"},{"issue":"11","key":"3933_CR36","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/j.1468-1331.2012.03698.x","volume":"19","author":"M Gattellari","year":"2012","unstructured":"Gattellari M, Goumas C, Worthington JM. A National epidemiological study of myasthenia Gravis in Australia. Eur J Neurol. 2012;19(11):1413\u201320.","journal-title":"Eur J Neurol"},{"issue":"18","key":"3933_CR37","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1093\/hmg\/ddr268","volume":"20","author":"A Iida","year":"2011","unstructured":"Iida A, Takahashi A, Kubo M, Saito S, Hosono N, Ohnishi Y, Kiyotani K, Mushiroda T, Nakajima M, Ozaki K, et al. A functional variant in ZNF512B is associated with susceptibility to amyotrophic lateral sclerosis in Japanese. Hum Mol Genet. 2011;20(18):3684\u201392.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"3933_CR38","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1212\/WNL.52.3.504","volume":"52","author":"BJ Traynor","year":"1999","unstructured":"Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in ireland, 1995\u20131997: a population-based study. Neurology. 1999;52(3):504\u20139.","journal-title":"Neurology"},{"issue":"4","key":"3933_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/17482960902721626","volume":"10","author":"B Marin","year":"2009","unstructured":"Marin B, Gil J, Preux PM, Funalot B, Couratier P. Incidence of amyotrophic lateral sclerosis in the limousin region of france, 1997\u20132007. Amyotroph Lateral Scler. 2009;10(4):216\u201320.","journal-title":"Amyotroph Lateral Scler"},{"issue":"6","key":"3933_CR40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/mus.24488","volume":"51","author":"H Jordan","year":"2015","unstructured":"Jordan H, Rechtman L, Wagner L, Kaye WE. Amyotrophic lateral sclerosis surveillance in Baltimore and Philadelphia. Muscle Nerve. 2015;51(6):815\u201321.","journal-title":"Muscle Nerve"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03933-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:52:35Z","timestamp":1757353955000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03933-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3933"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03933-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Beijing Tongren Hospital, Capital Medical University (TREC2023-KY006), with informed consent waived due to the retrospective and anonymized nature of the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"410"}}